Page 53 - 2019_06-Haematologica-web

The role of rituximab in ITP
analysis. Ann Oncol. 2016;27(3):390-397.
116. Van Daalen EE, Rizzo R, Kronbichler A, et al. Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis.
Ann Rheum Dis. 2017;76(6):1064-1069.
117. Wang J, Wiley JM, Luddy R, Greenberg J, Feuerstein MA, Bussel JB. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr.
2005;146(2):217-221.
118.Bennett CM, Rogers ZR, Kinnamon DD, et
al. Prospective phase 1 / 2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood. 2006;107(7):2639-2642.
119. Mueller BU, Bennett CM, Feldman HA, et al. One year follow-up of children and adoles-
cents with chronic immune thrombocy- topenic purpura (ITP) treated with ritux- imab. Pediatr Blood Cancer. 2009;52(2):259- 262.
120.Liang Y, Zhang L, Gao J, Hu D, Ai Y. Rituximab for children with immune throm- bocytopenia : a systematic review. PLoS One. 2012;7(5):e36698.
121.Taube T, Schmid H, Reinhard H, von Stackelberg A, Overberg US. Effect of a sin- gle dose of rituximab in chronic immune thrombocytopenic purpura in childhood. Haematologica. 2005;90(2):281–283.
ethasone. J Pediatr. 2017;191:225–231.
123. Parodi E, Rivetti E, Amendola G, et al. Long- term follow-up analysis after rituximab ther- apy in children with refractory symptomatic ITP : identification of factors predictive of a sustained response. Br J Haematol. 2009;144
(4):552–558.
124. Grace RF, Bennett CM, Ritchey AK, et al.
Response to steroids predicts response to rit- uximab in pediatric chronic immune throm- bocytopenia. Pediatr Blood Cancer. 2012;58(2):221-225.
125. Matsubara K, Takahashi Y, Hayakawa A, et al. Long-term follow-up of children with refractory immune thrombocytopenia treat- ed with rituximab. Int J Hematol. 2014;99 (4):429-436.
122.
Oved JH, Lee CSY, Bussel JB. Treatment of children with persistent and chronic idiopath- ic thrombocytopenic purpura: 4 infusions of rituximab and three 4-day cycles of dexam-
haematologica | 2019; 104(6)
1135